Georgia Tech

Georgia Tech, Emory Developing Urine-Based Dx to Guide Cancer Immunotherapies
Premium

The biological activity sensors in development consist of nanoparticles conjugated with a peptide substrate produce fluorescence in urine associated with immunotherapy response.

Breaking News

UK's NICE Reverses Course on Immunocore's Kimmtrak for Advanced Uveal Melanoma
Epsilogen Launches Phase Ib IgE Antibody Trial in Advanced Ovarian Cancer
Novartis Pens $2.9B Deal With PTC Therapeutics for Huntington's Disease Drug
Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint
Merck, Moderna Vax Trial Starts Enrolling Lung Cancer Patients at McGill University Health Center
Senti Biosciences Announces $37.6M PIPE Financing, Reports Early Data From Phase I CAR-NK Trial

Georgia Tech

Georgia Tech, Emory Developing Urine-Based Dx to Guide Cancer Immunotherapies Premium

UK's NICE Reverses Course on Immunocore's Kimmtrak for Advanced Uveal Melanoma

Epsilogen Launches Phase Ib IgE Antibody Trial in Advanced Ovarian Cancer

Novartis Pens $2.9B Deal With PTC Therapeutics for Huntington's Disease Drug

Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint

Merck, Moderna Vax Trial Starts Enrolling Lung Cancer Patients at McGill University Health Center

Senti Biosciences Announces $37.6M PIPE Financing, Reports Early Data From Phase I CAR-NK Trial

Georgia Tech, Emory Developing Urine-Based Dx to Guide Cancer Immunotherapies
Premium